Regeneron Pharmaceuticals Inc (REGN), Viropharma Inc (VPHM): Sanofi SA (ADR) (SNY)’s Interest Sparks Biotech Stocks in a Huge Week for Investors

Page 2 of 2

Peak sales estimates are strong for GlaxoSmithKline plc (ADR) (NYSE:GSK) and Theravance Inc (NASDAQ:THRX)’s drug, which some analysts project could pull in $1.4 billion annually in the near future if approved. It’s not quite a home run for Glaxo, which is looking for ways to complement blockbuster COPD and asthma treatment Advair, which, along with Seretide, made more than $8 billion last year. Still, an approval would help Glaxo in its attempts to beat the patent cliff, considering that Advair may face generic competition soon — and it’d help Theravance continue its recent run, considering shares of the biotech are up 83% year to date.

The article Sanofi’s Interest Sparks Biotech Stocks in a Huge Week for Investors originally appeared on Fool.com and is written by Dan Carroll.

Fool contributor Dan Carroll and The Motley Fool have no position in any of the stocks mentioned. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2